Redx Pharma Plc

Symbol: REDX.L




Market price today

  • -1.2879

    P/E Ratio

  • 2.0852

    PEG Ratio

  • 52.51M

    MRK Cap

  • 0.00%

    DIV Yield

Redx Pharma Plc (REDX-L) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Ms. Lisa Mary Whewell Anson
Full-time employees:101
Address:Alderley Park

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

General Outlook

In simple terms, Redx Pharma Plc has 422.091 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.890% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -7.850%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -7.891%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -1.293% return, is a testament to Redx Pharma Plc's adeptness in optimizing resource deployment. Redx Pharma Plc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -3.627%. Furthermore, the proficiency of Redx Pharma Plc in capital utilization is underscored by a remarkable -7.126% return on capital employed.

Stock Prices

Redx Pharma Plc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $18.7, while its low point bottomed out at $18.05. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Redx Pharma Plc's stock market.

Liquidity Ratios

Analyzing REDX.L liquidity ratios reveals its financial health of the firm. The current ratio of 110.92% gauges short-term asset coverage for liabilities. The quick ratio (89.13%) assesses immediate liquidity, while the cash ratio (86.12%) indicates cash reserves.

Current Ratio110.92%
Quick Ratio89.13%
Cash Ratio86.12%

Profitability Ratios

REDX.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -780.30% underscores its earnings before tax deductions. The effective tax rate stands at -1.12%, revealing its tax efficiency. The net income per EBT, 101.12%, and the EBT per EBIT, 99.41%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -784.96%, we grasp its operational profitability.

Pretax Profit Margin-780.30%
Effective Tax Rate-1.12%
Net Income per EBT101.12%
EBT per EBIT99.41%
EBIT per Revenue-784.96%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.11, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 664.87% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding89
Operating Cycle54.90
Days of Payables Outstanding2955
Cash Conversion Cycle-2900
Receivables Turnover6.65
Payables Turnover0.12
Fixed Asset Turnover2.17
Asset Turnover0.16

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.10, and free cash flow per share, -0.10, depict cash generation on a per-share basis. The cash per share value, 0.05, showcases liquidity position. Lastly, the operating cash flow sales ratio, -8.27, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-0.10
Free Cash Flow per Share-0.10
Cash per Share0.05
Operating Cash Flow Sales Ratio-8.27
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-1.97
Short Term Coverage Ratio-2.12
Capital Expenditure Coverage Ratio-178.19
Dividend Paid and Capex Coverage Ratio-178.19

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 68.97%, highlights its total liabilities relative to assets. With a debt-equity ratio of 5.27, we discern the balance between debt and equity financing. The long-term debt to capitalization, 27.52%, and total debt to capitalization, 84.05%, ratios shed light on its capital structure. An interest coverage of -18.31 indicates its ability to manage interest expenses.

Debt Ratio68.97%
Debt Equity Ratio5.27
Long Term Debt to Capitalization27.52%
Total Debt to Capitalization84.05%
Interest Coverage-18.31
Cash Flow to Debt Ratio-1.97
Company Equity Multiplier7.64

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.01, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.10, reflects the portion of profit attributed to each share. The book value per share, 0.01, represents the net asset value distributed per share, while the tangible book value per share, 0.01, excludes intangible assets.

Revenue Per Share0.01
Net Income Per Share-0.10
Book Value Per Share0.01
Tangible Book Value Per Share0.01
Shareholders Equity Per Share0.01
Interest Debt Per Share0.06

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -77.52%, indicates top-line expansion, while the gross profit growth, -82.65%, reveals profitability trends. EBIT growth, -107.92%, and operating income growth, -107.92%, offer insights into operational profitability progression. The net income growth, -84.15%, showcases bottom-line expansion, and the EPS growth, -61.76%, measures the growth in earnings per share.

Revenue Growth-77.52%
Gross Profit Growth-82.65%
EBIT Growth-107.92%
Operating Income Growth-107.92%
Net Income Growth-84.15%
EPS Growth-61.76%
EPS Diluted Growth-61.76%
Weighted Average Shares Growth13.84%
Weighted Average Shares Diluted Growth13.84%
Operating Cash Flow Growth-310.24%
Free Cash Flow Growth-300.16%
5-Year Revenue Growth per Share1130.47%
3-Year Revenue Growth per Share-62.45%
10-Year Operating CF Growth per Share-70.90%
5-Year Operating CF Growth per Share23.59%
3-Year Operating CF Growth per Share-4568.79%
10-Year Net Income Growth per Share-101.64%
5-Year Net Income Growth per Share-41.60%
3-Year Net Income Growth per Share-82.82%
10-Year Shareholders Equity Growth per Share-16.07%
5-Year Shareholders Equity Growth per Share-78.01%
3-Year Shareholders Equity Growth per Share-36.57%
Receivables Growth-88.56%
Inventory Growth100.00%
Asset Growth-58.97%
Book Value per Share Growth-91.16%
Debt Growth-3.41%
R&D Expense Growth1.94%
SGA Expenses Growth-21.12%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 86,665,979.08, captures the company's total value, considering both debt and equity. Income quality, 1.05, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 1.92, gauges operational efficiency, while the research and development to revenue, 692.93%, highlights investment in innovation. The ratio of intangibles to total assets, 1.54%, indicates the value of non-physical assets, and capex to operating cash flow, 0.56%, measures reinvestment capability.

Enterprise Value86,665,979.08
Income Quality1.05
Sales General and Administrative to Revenue1.92
Research and Development to Revenue692.93%
Intangibles to Total Assets1.54%
Capex to Operating Cash Flow0.56%
Capex to Revenue-4.64%
Capex to Depreciation-20.31%
Stock-Based Compensation to Revenue76.01%
Graham Number0.15
Return on Tangible Assets-131.35%
Graham Net Net-0.01
Working Capital2,295,000
Tangible Asset Value2,961,000
Net Current Asset Value1,021,000
Invested Capital5
Average Receivables3,078,000
Average Payables4,857,000
Average Inventory-2,762,000
Days Sales Outstanding55
Days Payables Outstanding1428

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 12.73, and the price to book ratio, 12.73, reflect the market's valuation relative to the company's book value. The price to sales ratio, 12.50, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -1.50, and price to operating cash flows, -1.23, gauge market valuation against cash flow metrics.

Price Book Value Ratio12.73
Price to Book Ratio12.73
Price to Sales Ratio12.50
Price Cash Flow Ratio-1.23
Price Earnings to Growth Ratio2.09
Enterprise Value Multiple-1.65
Price Fair Value12.73
Price to Operating Cash Flow Ratio-1.23
Price to Free Cash Flows Ratio-1.50
Price to Tangible Book Ratio25.95
Enterprise Value to Sales20.62
Enterprise Value Over EBITDA-2.96
EV to Operating Cash Flow-2.49
Earnings Yield-38.08%
Free Cash Flow Yield-40.13%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Redx Pharma Plc (REDX.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.288 in 2024.

What is the ticker symbol of Redx Pharma Plc stock?

The ticker symbol of Redx Pharma Plc stock is REDX.L.

What is company IPO date?

IPO date of Redx Pharma Plc is 2015-03-27.

What is company current share price?

Current share price is 12.750 GBp.

What is stock market cap today?

The market cap of stock today is 52513099.000.

What is PEG ratio in 2024?

The current 2.085 is 2.085 in 2024.

What is the number of employees in 2024?

In 2024 the company has 101.